Background/Aim: Evidence demonstrating an important role of the intestinal microbiota in the incidence of allergic disorders has led to the concept of using probiotics as possible antiallergic therapy. This study aimed to select a bacterial strain with the best antiallergic treatment effects from a panel of 6 bacterial strains in a mouse model of ovalbumin(OVA)-allergic asthma. Methods: OVA-sensitized BALB/c mice were orally administered the bacterial strains Bifidobacterium breve M-16V, B. infantis NumRes251, B. animalis NumRes252 and NumRes253, Lactobacillus plantarum NumRes8 and L. rhamnosus NumRes6. After challenge by OVA inhalation in the lungs, the response to methacholine was measured. Pulmonary inflammation was assessed by analyzing bronchoalveolar lavage fluid for the presence of eosinophils, neutrophils, macrophages and lymphocytes and for interleukin 4, interleukin 5, interleukin 10 and interferon-γ. OVA-specific IgE, IgG1 and IgG2a were measured in serum. Next, the effect on acute allergic skin reaction was measured after treatment with B. breve M-16V and L. plantarum NumRes8. Results: Of the panel of 6 strains, B. breve M-16V and L. plantarum NumRes8 inhibited (1) the response to methacholine, (2) reduced the number of eosinophils in the bronchoalveolar lavage fluid, (3) reduced both OVA-specific IgE and (4) OVA-specific IgG1, whereas the other strains did not affect all these parameters simultaneously. B. breve M-16V but not L. plantarum NumRes8 reduced interleukin 4, interleukin 5 and interleukin 10. Furthermore, B. breve M-16V but not L. plantarum NumRes8 reduced acute allergic skin reactions to OVA. Conclusion: B. breve M-16V was identified as the most potent antiallergic strain.

Journal Section:
Editor's choice
Keywords:
Ovalbumin-allergic mouse model, Allergic inflammation, <italic>Bifidobacterium breve</italic> M-16V, Probiotics
1.
Beasley R: Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998;351:1225–1232.
2.
Wadonda-Kabondo N, Sterne JA, Golding J, Kennedy CT, Archer CB, Dunnill MG: A prospective study of the prevalence and incidence of atopic dermatitis in children aged 0–42 months. Br J Dermatol 2003;149:1023–1028.
3.
Strachan DP: Hay fever, hygiene, and household size. BMJ 1989;299:1259–1260.
4.
Rook GA, Adams V, Hunt J, Palmer R, Martinelli R, Brunet LR: Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin Immunopathol 2004;25:237–255.
5.
Romagnani S: The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004;112:352–363.
6.
Guarner F, Bourdet-Sicard R, Brandtzaeg P, Gill HS, McGuirk P, van Eden W, Versalovic J, Weinstock JV, Rook GA: Mechanisms of disease: the hygiene hypothesis revisited. Nat Clin Pract Gastroenterol Hepatol 2006;3:275–284.
7.
Bjorksten B, Naaber P, Sepp E, Mikelsaar M: The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 1999;29:342–346.
8.
Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M: Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001;108:516–520.
9.
Watanabe S, Narisawa Y, Arase S, Okamatsu H, Ikenaga T, Tajiri Y, Kumemura M: Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J Allergy Clin Immunol 2003;111:587–591.
10.
Kalliomäki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E: Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001;107:129–134.
11.
Ouwehand A, Isolauri E, Salminen S: The role of the intestinal microflora for the development of the immune system in early childhood. Eur J Nutr 2002;41(suppl 1):I32–I37.
12.
Kalliomäki M, Isolauri E: Role of intestinal flora in the development of allergy. Curr Opin Allergy Clin Immunol 2003;3:15–20.
13.
Araya M, Gopal P, Lindgren SE, Lodi R, Oliver G, Saxelin ML, Servin AL: Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria, Cordoba, 2001.
14.
Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S: Probiotics in the management of atopic eczema. Clin Exp Allergy 2000;30:1604–1610.
15.
Pessi T, Sutas Y, Hurme M, Isolauri E: Interleukin-10 generation in atopic children following oral <i>Lactobacillus rhamnosus</i> GG. Clin Exp Allergy 2000;30:1804–1808.
16.
Rautava S, Kalliomäki M, Isolauri E: Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002;109:119–121.
17.
Pohjavuori E, Viljanen M, Korpela R, Kuitunen M, Tiittanen M, Vaarala O, Savilahti E: Lactobacillus GG effect in increasing IFN-γ production in infants with cow’s milk allergy. J Allergy Clin Immunol 2004;114:131–136.
18.
Prescott SL, Dunstan JA, Hale J, Breckler L, Lehmann H, Weston S, Richmond P: Clinical effects of probiotics are associated with increased interferon-γresponses in very young children with atopic dermatitis. Clin Exp Allergy 2005;35:1557–1564.
19.
Fujii T, Ohtsuka Y, Lee T, Kudo T, Shoji H, Sato H, Nagata S, Shimizu T, Yamashiro Y: <i>Bifidobacterium breve</i> enhances transforming growth factor β1 signaling by regulating Smad7 expression in preterm infants. J Pediatr Gastroenterol Nutr 2006;43:83–88.
20.
Lee J, Seto D, Bielory L: Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol 2008;121:116–121.
21.
Kopp MV, Salfeld P: Probiotics and prevention of allergic disease. Curr Opin Clin Nutr Metab Care 2009;12:298–303.
22.
Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E: Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076–1079.
23.
Viljanen M, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Kuitunen M: Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005;60:494–500.
24.
Grüber C, Wendt M, Sulser C, Lau S, Kulig K, Wahn U, Werfel T, Niggemann B: Randomized, placebo-controlled trial of <i>Lactobacillus rhamnosus</i> GG as treatment of atopic dermatitis in infancy. Allergy 2007;62:1270–1276.
25.
Kopp MV, Hennemuth I, Heinzmann A, Urbanek R: Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics 2008;121:e850–e856.
26.
Blumer N, Sel S, Virna S, Patrascan CC, Zimmermann S, Herz U, Renz H, Garn H: Perinatal maternal application of <i>Lactobacillus rhamnosus</i> GG suppresses allergic airway inflammation in mouse offspring. Clin Exp Allergy 2007;37:348–357.
27.
Feleszko W, Jaworska J, Rha RD, Steinhausen S, Avagyan A, Jaudszus A, Ahrens B, Groneberg DA, Wahn U, Hamelmann E: Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. Clin Exp Allergy 2007;37:498–505.
28.
Lane D: 16S/23S rRNA sequencing; in Stackebrandt E, Goodfellow M (eds): Nucleic Acid Techniques in Bacterial Systematics. New York, Wiley, 1991, pp 115–175.
29.
Tilsala-Timisjärvi A, Alatossava T: Development of oligonucleotide primers from the 16S-23S rRNA intergenic sequences for identifying different dairy and probiotic lactic acid bacteria by PCR. Int J Food Microbiol 1997;35:49–56.
30.
Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW: Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997;156:766–775.
31.
Vos AP, van Esch BC, Stahl B, M’Rabet L, Folkerts G, Nijkamp FP, Garssen J: Dietary supplementation with specific oligosaccharide mixtures decreases parameters of allergic asthma in mice. Int Immunopharmacol 2007;7:1582–1587.
32.
Forsythe P, Inman MD, Bienenstock J: Oral treatment with live <i>Lactobacillus reuteri</i> inhibits the allergic airway response in mice. Am J Respir Crit Care Med 2007;175:561–569.
33.
De Bie JJ, Hessel EM, Van Ark I, Van Esch B, Hofman G, Nijkamp FP, Van Oosterhout AJ: Effect of dexamethasone and endogenous corticosterone on airway hyperresponsiveness and eosinophilia in the mouse. Br J Pharmacol 1996;119:1484–1490.
34.
Hessel EM, Van Oosterhout AJ, Van Ark I, Van Esch B, Hofman G, Van Loveren H, Savelkoul HF, Nijkamp FP: Development of airway hyperresponsiveness is dependent on interferon-γ and independent of eosinophil infiltration. Am J Respir Cell Mol Biol 1997;16:325–334.
35.
Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG: Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996;183:195–201.
36.
Wardlaw AJ, Brightling C, Green R, Woltmann G, Pavord I: Eosinophils in asthma and other allergic diseases. Br Med Bull 2000;56:985–1003.
37.
Fujiwara D, Inoue S, Wakabayashi H, Fujii T: The anti-allergic effects of lactic acid bacteria are strain dependent and mediated by effects on both Th1/Th2 cytokine expression and balance. Int Arch Allergy Immunol 2004;135:205–215.
38.
Takahashi N, Kitazawa H, Shimosato T, Iwabuchi N, Xiao JZ, Iwatsuki K, Kokubo S, Saito T: An immunostimulatory DNA sequence from a probiotic strain of <i>Bifidobacterium longum</i> inhibits IgE production in vitro. FEMS Immunol Med Microbiol 2006; 46:461–469.
39.
Takahashi N, Kitazawa H, Iwabuchi N, Xiao JZ, Miyaji K, Iwatsuki K, Saito T: Immunostimulatory oligodeoxynucleotide from <i>Bifidobacterium longum</i> suppresses Th2 immune responses in a murine model. Clin Exp Immunol 2006;145:130–138.
40.
Takahashi N, Kitazawa H, Iwabuchi N, Xiao JZ, Miyaji K, Iwatsuki K, Saito T: Oral administration of an immunostimulatory DNA sequence from <i>Bifidobacterium longum</i> improves Th1/Th2 balance in a murine model. Biosci Biotechnol Biochem 2006;70:2013–2017.
41.
Inoue Y, Iwabuchi N, Xiao JZ, Yaeshima T, Iwatsuki K: Suppressive effects of <i>Bifidobacterium breve</i> strain M-16V on T-helper type 2 immune responses in a murine model. Biol Pharm Bull 2009;32:760–763.
42.
Taniuchi S, Hattori K, Yamamoto A, Sasai M, Hatano Y, Kojima T, Kobayashi Y, Iwamoto H, Yaeshima T: Administration of bifidobacterium to infants with atopic dermatitis: changes in fecal microflora and clinical symptoms. J Appl Res 2005;5:387–396.
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2009
You do not currently have access to this content.